Un-Audited Financial Results For The Period Ended 30.06.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Godavari Drugs reported weak Q1 FY26 results with revenue from operations falling to ₹2,381.13 lakhs from ₹3,220.75 lakhs in the same quarter last year, a drop of about 26%. Total income (including other income) declined roughly 28% YoY to ₹2,382.35 lakhs. Net profit for the quarter came in at ₹104.06 lakhs versus ₹153.08 lakhs in Q1 FY25, down around 32%, and EPS slipped from ₹2.17 to ₹1.38. Cost of materials consumed fell sharply along with revenue, while finance costs also declined from ₹143.52 lakhs to ₹100.46 lakhs, keeping operating margins broadly stable at around 12%. The auditor (Ayyadevara & Co.) issued an unmodified limited review report with no qualifications or emphasis of matter.
Negative near-term sentiment for shareholders as both top line and bottom line contracted sharply YoY, even though the company remains profitable and margins held steady. Investors may watch for signs of demand recovery in upcoming quarters and any commentary on why revenues shrank.